- Home
- PERF vs SLDB Comparison
PERF vs SLDB Comparison
Compare PERF & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERF
- SLDB
- Stock Information
- Founded
- PERF 2015
- SLDB 2013
- Country
- PERF Taiwan
- SLDB United States
- Employees
- PERF N/A
- SLDB N/A
- Industry
- PERF Computer Software: Prepackaged Software
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PERF Technology
- SLDB Health Care
- Exchange
- PERF Nasdaq
- SLDB Nasdaq
- Market Cap
- PERF 197.6M
- SLDB 193.8M
- IPO Year
- PERF N/A
- SLDB 2018
- Fundamental
- Price
- PERF $1.85
- SLDB $5.41
- Analyst Decision
- PERF Buy
- SLDB Strong Buy
- Analyst Count
- PERF 2
- SLDB 10
- Target Price
- PERF $4.00
- SLDB $17.50
- AVG Volume (30 Days)
- PERF 59.2K
- SLDB 308.2K
- Earning Date
- PERF 10-29-2024
- SLDB 11-06-2024
- Dividend Yield
- PERF N/A
- SLDB N/A
- EPS Growth
- PERF N/A
- SLDB N/A
- EPS
- PERF 0.05
- SLDB N/A
- Revenue
- PERF $58,445,000.00
- SLDB N/A
- Revenue This Year
- PERF $15.77
- SLDB N/A
- Revenue Next Year
- PERF $13.89
- SLDB N/A
- P/E Ratio
- PERF $36.84
- SLDB N/A
- Revenue Growth
- PERF 15.84
- SLDB N/A
- 52 Week Low
- PERF $1.70
- SLDB $2.63
- 52 Week High
- PERF $3.77
- SLDB $15.05
- Technical
- Relative Strength Index (RSI)
- PERF 46.80
- SLDB 44.96
- Support Level
- PERF $1.78
- SLDB $4.61
- Resistance Level
- PERF $1.92
- SLDB $5.19
- Average True Range (ATR)
- PERF 0.08
- SLDB 0.43
- MACD
- PERF 0.00
- SLDB 0.01
- Stochastic Oscillator
- PERF 45.63
- SLDB 46.78
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions that are ultra-personalized, interactive and engaging, from online to in-store through beauty mirrors. Geographically, the company has a presence in the United States, France, Japan and Others.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.